Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
(2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA., The Lancet ., doi : 10.1016/S0140-6736(23)01053-X.
View CBS News In CBS News App Open Chrome Safari Continue
Reconstitution volume depends on the vial size and the working concentration required by the research protocol
Mass spectrometry confirms molecular weight matches the target compound
Unpredictable side effects and safety While microdosing is used to reduce the risk of side effects, this is not supported by any clinical trials
In addition, glucagon like peptide-1 receptor agonists (GLP-1RAs) can be combined with GLP-1Rs, playing the same role as GLP-1
US$ 28.84
US$ 22.81
US$ 27.10
